Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

A framework for modern-day management and assessment of frailty

Care of Older People – August 2018 digest.
A summary of this collaborative stakeholder initiative from the UK.

Strain WD, Hope SV, Green A, Kar P, Valabhji J, Sinclair AJ (2018) Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med 35: 838–45

  • This collaborative stakeholder initiative from the UK presents a framework for assessing frailty status in older people and guidelines for the management of diabetes according to frailty status.
  • The frailty assessment pathway begins with clinical review and a validated frailty assessment tool in primary care, with opportunity for referral if required. An initial management plan can then be agreed with the patient with input from diabetes specialists and geriatricians.
  • The features of a modern-day diabetes service for older people are then outlined, including inter-professional working, a strategy to minimise medication risk, an active deprescribing policy, review of diabetes and frailty status at the time of care home residency, an easy-access end-of-life care pathway and use of additional clinical outcomes in audit.
  • The proposed treatment guidelines suggest targets of 58, 64 and 70 mmol/mol (7.5%, 8.0% and 8.5%) in fit older adults, moderate frailty and severe frailty, respectively, while the thresholds for deprescribing are 53, 58 and 64 mmol/mol (7.0%, 7.5% and 8.0%).
  • In general, with increasing frailty, deprescribing should involve stopping sulfonylureas and short-acting insulins. Pioglitazone should be avoided because of heart failure risk. Metformin use should take renal function into account.
  • In people with severe frailty, therapies that promote weight loss should be avoided as they may exacerbate sarcopenia.

Click here to access the article in full.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.